JP2023516533A - マルチビーム神経調節技術 - Google Patents
マルチビーム神経調節技術 Download PDFInfo
- Publication number
- JP2023516533A JP2023516533A JP2022535040A JP2022535040A JP2023516533A JP 2023516533 A JP2023516533 A JP 2023516533A JP 2022535040 A JP2022535040 A JP 2022535040A JP 2022535040 A JP2022535040 A JP 2022535040A JP 2023516533 A JP2023516533 A JP 2023516533A
- Authority
- JP
- Japan
- Prior art keywords
- interest
- organ
- regions
- target
- ultrasound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004007 neuromodulation Effects 0.000 title claims abstract description 27
- 238000005516 engineering process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000006073 displacement reaction Methods 0.000 claims abstract description 19
- 238000002604 ultrasonography Methods 0.000 claims description 104
- 210000001519 tissue Anatomy 0.000 claims description 76
- 210000000056 organ Anatomy 0.000 claims description 70
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 30
- 239000008103 glucose Substances 0.000 claims description 30
- 210000000952 spleen Anatomy 0.000 claims description 26
- 210000000496 pancreas Anatomy 0.000 claims description 25
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 12
- 210000002569 neuron Anatomy 0.000 claims description 11
- 238000009826 distribution Methods 0.000 claims description 8
- 210000000225 synapse Anatomy 0.000 claims description 7
- 210000000063 presynaptic terminal Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 description 60
- 238000011282 treatment Methods 0.000 description 41
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000004044 response Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000003393 splenic effect Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 230000010004 neural pathway Effects 0.000 description 5
- 230000003227 neuromodulating effect Effects 0.000 description 5
- 230000003376 axonal effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000118 neural pathway Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000009997 humoral pathway Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/0026—Stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0052—Ultrasound therapy using the same transducer for therapy and imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0073—Ultrasound therapy using multiple frequencies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0082—Scanning transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
- A61N2007/0091—Beam steering with moving parts, e.g. transducers, lenses, reflectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0086—Beam steering
- A61N2007/0095—Beam steering by modifying an excitation signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
- A61N2007/027—Localised ultrasound hyperthermia with multiple foci created simultaneously
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Description
Claims (21)
- 複数の要素を含む少なくとも1つの超音波トランスデューサ、および
前記対象に適用される超音波エネルギーの線量を制御するように構成されたコントローラ、を含み、前記コントローラは、
前記超音波トランスデューサから前記対象の組織の画像データを受信すること、
前記組織の前記画像データを前記組織を表す複数のセグメントに分割すること、
前記超音波トランスデューサを複数の対象領域に集束させること、各対象領域は、前記複数のセグメントのうちの異なるセグメントの内部に配置される、および
前記複数の対象領域間に分配された超音波エネルギーを適用して各対象領域の組織変位を引き起こすように前記超音波トランスデューサを制御することに対して構成される、超音波システム。 - 前記組織が、第1の器官、および前記第1の器官とは異なる第2の器官を含み、前記複数の対象領域のうちの第1の対象領域が前記第1の器官にあり、前記複数の対象領域のうちの第2の対象領域が前記第2の器官にある、請求項1に記載のシステム。
- 前記線量の少なくとも75%が前記第1の器官に適用される、請求項2に記載のシステム。
- 前記第1の器官が、膵臓、脾臓、または肝臓である、請求項2に記載のシステム。
- 前記組織が器官を含み、前記複数の対象領域が前記器官にある、請求項1に記載のシステム。
- 前記コントローラは、前記複数のセグメントの個々のセグメントがある期間にわたって選択された超音波エネルギーの閾値を超える超音波エネルギーを受けないように、前記線量の適用を制御するように構成される、請求項1に記載のシステム。
- 前記コントローラは、前記超音波エネルギーを各対象領域に同時に適用するように構成される、請求項1に記載のシステム。
- 前記コントローラは、前記超音波エネルギーを各対象領域に直列に適用するように構成される、請求項1に記載のシステム。
- 前記コントローラは、前記複数の対象領域のうちの第1の対象領域に第1の超音波エネルギーを適用するように前記複数の要素の第1のサブセットを制御し、前記複数の対象領域のうちの第2の対象領域に第2の超音波エネルギーを適用するように前記複数の超音波要素の第2のサブセットを制御するように構成される、請求項1に記載のシステム。
- 前記第1の対象領域が第1の器官にあり、前記第2の対象領域が前記第1の器官とは異なる第2の器官にあり、前記第1の超音波エネルギーは前記第2の超音波エネルギーと比べて前記線量のより大きな割合である、請求項9に記載のシステム。
- 前記組織の変位が、1つまたは複数の分子のベースラインに対する濃度の変化をモニタリングすることによって評価される、請求項1に記載のシステム。
- 前記1つまたは複数の分子のうちの第1の分子がTNF-αであり、前記1つまたは複数の分子のうちの第2の分子がグルコースである、請求項11に記載のシステム。
- 複数の対象領域間で超音波エネルギー線量を分配することであって、前記複数の対象領域の各個々の対象領域は、前記超音波エネルギー線量の一部を受け、前記複数の対象領域への累積適用超音波エネルギーは、前記超音波エネルギー線量にほぼ等しい、分配すること、
前記超音波エネルギー線量の有効性を評価すること、および
前記評価することに基づいて、前記神経調節治療の後続の超音波エネルギー線量を適用するように命令を修正することを含む、方法。 - 前記命令を修正することは、前記後続の超音波エネルギー線量の一部が分配される異なる複数の対象領域を選択することを含む、請求項13に記載の方法。
- 前記命令を修正することは、前記後続の超音波エネルギー線量の前記複数の対象領域間の超音波エネルギーの相対的な分布を修正することを含む、請求項13に記載の方法。
- ベースラインに対する対象の分子の濃度の変化が所定の閾値より低い場合、前記相対的な分布が、前記複数の対象領域の個々の対象領域に適用される前記後続の超音波エネルギー線量の割合を増加させるように変更される、請求項15に記載の方法。
- 前記個々の対象領域が第1の器官にあり、第2の器官の前記複数の対象領域の対象領域に適用される割合が適宜減少する、請求項16に記載の方法。
- 前記対象の組織の画像データを受信すること、
前記組織の前記画像データを複数のセグメントに分割すること、
前記複数のセグメントのそれぞれのセグメントに関連する前記組織の複数の対象領域を選択すること、および
前記複数の対象領域の間に分布する超音波エネルギー線量を適用するように前記超音波トランスデューサを制御することであって、前記複数の対象領域の少なくとも1つの対象領域がニューロンの少なくとも1つの軸索末端を含み、前記軸索末端が非ニューロン細胞とシナプスを形成する、制御することを含む、方法。 - 異なる複数のセグメントを選択することと、前記異なる複数の対象領域間に分配された後続の超音波エネルギー線量を適用するように前記超音波トランスデューサを制御することとを含む、請求項18に記載の方法。
- 前記複数の対象領域を選択することが、第1の器官における少なくとも1つの対象領域、および第2の器官における少なくとも1つの対象領域を選択することを含む、請求項18に記載の方法。
- 前記複数のセグメントの各セグメントは、互いに対してほぼ同じ体積である、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/709,717 US11786760B2 (en) | 2019-12-10 | 2019-12-10 | Multi-beam neuromodulation techniques |
US16/709,717 | 2019-12-10 | ||
PCT/US2020/061327 WO2021118783A1 (en) | 2019-12-10 | 2020-11-19 | Multi-beam neuromodulation techniques |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023516533A true JP2023516533A (ja) | 2023-04-20 |
Family
ID=76209362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022535040A Pending JP2023516533A (ja) | 2019-12-10 | 2020-11-19 | マルチビーム神経調節技術 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11786760B2 (ja) |
EP (1) | EP4072669A4 (ja) |
JP (1) | JP2023516533A (ja) |
CN (1) | CN114786770A (ja) |
WO (1) | WO2021118783A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113409273B (zh) * | 2021-06-21 | 2023-04-07 | 上海联影医疗科技股份有限公司 | 一种图像分析方法、装置、设备和介质 |
NO20221187A1 (en) * | 2022-11-04 | 2024-05-06 | Exact Therapeutics As | Method and system for calculating a point estimate of an ultrasound dose |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7510536B2 (en) | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
US20100081893A1 (en) | 2008-09-19 | 2010-04-01 | Physiosonics, Inc. | Acoustic palpation using non-invasive ultrasound techniques to identify and localize tissue eliciting biological responses and target treatments |
US9592409B2 (en) * | 2002-04-30 | 2017-03-14 | The Regents Of The University Of California | Methods for modifying electrical currents in neuronal circuits |
US20050075702A1 (en) | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US7662114B2 (en) * | 2004-03-02 | 2010-02-16 | Focus Surgery, Inc. | Ultrasound phased arrays |
US9011336B2 (en) | 2004-09-16 | 2015-04-21 | Guided Therapy Systems, Llc | Method and system for combined energy therapy profile |
US8078283B2 (en) | 2006-06-20 | 2011-12-13 | Ebr Systems, Inc. | Systems and methods for implantable leadless bone stimulation |
US20100030076A1 (en) | 2006-08-01 | 2010-02-04 | Kobi Vortman | Systems and Methods for Simultaneously Treating Multiple Target Sites |
US20080033297A1 (en) | 2006-08-02 | 2008-02-07 | Sliwa John W | Neural tissue stimulation, assessment, mapping, and therapy utilizing targeted acoustic mechanisms |
US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
CN101587586B (zh) * | 2008-05-20 | 2013-07-24 | 株式会社理光 | 一种图像处理装置及图像处理方法 |
US9174065B2 (en) | 2009-10-12 | 2015-11-03 | Kona Medical, Inc. | Energetic modulation of nerves |
US20120197163A1 (en) * | 2011-01-27 | 2012-08-02 | Mishelevich David J | Patterned control of ultrasound for neuromodulation |
EP2519324B1 (en) * | 2009-12-28 | 2017-10-25 | Profound Medical Inc. | Therapeutic apparatus |
FR2960789B1 (fr) * | 2010-06-07 | 2013-07-19 | Image Guided Therapy | Transducteur d'ultrasons a usage medical |
EP3406299B1 (en) * | 2010-06-09 | 2021-08-04 | Regents of the University of Minnesota | Dual mode ultrasound transducer (dmut) system for controlling delivery of ultrasound therapy |
US20130211396A1 (en) * | 2010-10-18 | 2013-08-15 | CardioSonic Ltd. | Tissue treatment |
US8968205B2 (en) * | 2011-02-10 | 2015-03-03 | Siemens Medical Solutions Usa, Inc. | Sub-aperture control in high intensity focused ultrasound |
AU2012347470B2 (en) | 2011-12-09 | 2017-02-02 | Medtronic Ireland Manufacturing Unlimited Company | Therapeutic neuromodulation of the hepatic system |
EP2624004A1 (en) * | 2012-02-06 | 2013-08-07 | Koninklijke Philips Electronics N.V. | Temperature determination using magnetic resonance B1 field mapping |
US11167154B2 (en) * | 2012-08-22 | 2021-11-09 | Medtronic, Inc. | Ultrasound diagnostic and therapy management system and associated method |
EP2914341B1 (en) * | 2012-11-05 | 2020-04-15 | Regents of the University of Minnesota | Non-invasive lung pacing |
WO2015039995A1 (en) * | 2013-09-19 | 2015-03-26 | Koninklijke Philips N.V. | High-dose rate brachytherapy system |
US20150141874A1 (en) | 2013-11-18 | 2015-05-21 | Kitchener Clark Wilson | Multi-beam Ultrasound Device |
CN108024899A (zh) * | 2015-07-06 | 2018-05-11 | 科纳医药股份有限公司 | 组合式病人平台 |
US20170281982A1 (en) * | 2016-03-31 | 2017-10-05 | Family Health International | Methods and systems for generating an occlusion using ultrasound |
WO2017212489A2 (en) * | 2016-06-06 | 2017-12-14 | Archimedus Medical Ltd. | Ultrasound transducer and system |
US10803593B2 (en) * | 2016-09-19 | 2020-10-13 | Siemens Healthcare Gmbh | Method and system for image compression |
US20200046992A1 (en) * | 2016-10-31 | 2020-02-13 | The Feinstein Institute For Medical Research | Techniques for neuromodulation using electromagnetic energy |
WO2018104350A1 (en) * | 2016-12-07 | 2018-06-14 | Koninklijke Philips N.V. | Ultrasonic sonothrombolysis treatment planning |
US11259781B2 (en) * | 2016-12-16 | 2022-03-01 | Koninklijke Philips N.V. | Adaptive pulsing for sonothrombolysis treatment |
WO2018185767A1 (en) * | 2017-04-03 | 2018-10-11 | Mdsg Innovation Ltd. | Apparatus and method for treating kidneys |
CN118787381A (zh) * | 2017-09-13 | 2024-10-18 | 奥卓霍姆有限责任公司 | 具有cmut阵列和固态冷却的医疗设备以及相关方法和系统 |
US20190247066A1 (en) * | 2018-02-12 | 2019-08-15 | Koninklijke Philips N.V. | Treatment of myocardial infarction using sonothrombolytic ultrasound |
US20200302825A1 (en) * | 2019-03-21 | 2020-09-24 | Dan Sachs | Automated selection and titration of sensory stimuli to induce a target pattern of autonomic nervous system activity |
-
2019
- 2019-12-10 US US16/709,717 patent/US11786760B2/en active Active
-
2020
- 2020-11-19 EP EP20898291.8A patent/EP4072669A4/en active Pending
- 2020-11-19 CN CN202080085241.4A patent/CN114786770A/zh active Pending
- 2020-11-19 WO PCT/US2020/061327 patent/WO2021118783A1/en unknown
- 2020-11-19 JP JP2022535040A patent/JP2023516533A/ja active Pending
-
2023
- 2023-09-14 US US18/467,552 patent/US20240001159A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4072669A4 (en) | 2023-12-20 |
WO2021118783A1 (en) | 2021-06-17 |
US20210170203A1 (en) | 2021-06-10 |
US11786760B2 (en) | 2023-10-17 |
CN114786770A (zh) | 2022-07-22 |
US20240001159A1 (en) | 2024-01-04 |
EP4072669A1 (en) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200046992A1 (en) | Techniques for neuromodulation using electromagnetic energy | |
US20170246481A1 (en) | Devices and methods for optimized neuromodulation and their application | |
JP6498754B2 (ja) | 患者入力に応答する知覚以下変調 | |
CN104519960B (zh) | 超声诊断和治疗管理系统及相关联的方法 | |
JP6505835B2 (ja) | ターゲット組織のための変調場の目的関数に固有の神経変調 | |
JP6580678B2 (ja) | バースト刺激を用いた神経変調 | |
US20160001096A1 (en) | Devices and methods for optimized neuromodulation and their application | |
EP2699310B1 (en) | Apparatus for assessing neural activation | |
JP6621812B2 (ja) | 場トロールを用いる神経組織の知覚較正 | |
US20130281890A1 (en) | Neuromodulation devices and methods | |
US20090163982A1 (en) | Applications of the stimulation of neural tissue using light | |
EP3490438A1 (en) | Methods and systems for peripheral nerve modulation using focused ultrasound | |
US20240001159A1 (en) | Multi-beam neuromodulation techniques | |
US20130184728A1 (en) | Ultrasound Neuromodulation for Diagnosis and Other-Modality Preplanning | |
JP2022546950A (ja) | 治療用ニューロモジュレーションの送達 | |
JP2024096729A (ja) | 神経調節技術 | |
US20230226380A1 (en) | Noninvasive tissue displacement control and monitoring for neuromodulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20221222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230907 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240807 |